Aerothricin derivatives
View Patent ↗The present invention relates to novel Aerothricins represented by the Formula (I), and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition comprising an Aerothricin of the Formula (I) and a pharmaceutically acceptable carrier. Furthermore, the present invention relates to the use of such Aerothricins for the preparation of medicaments, as well as to processes for the preparation of the Aerothricins of the Formula (I).
1. A compound of the formula:
wherein
R 1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;
R 2 is hydrogen or methyl;
R 3 is hydrogen or hydroxy;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein R 1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-amino)amino]aleryl]amino, or (L)-ornityl-(D)-ornitylamino.
3. The compound according to claim 1 , wherein R 2 and R 3 are hydrogen.
4. The compound according to claim 1 , wherein R 1 is N-(3-aminopropyl)-N-[(2S)2,5-diaminovaleryl]amino, and R 2 and R 3 are hydrogen.
5. The compound according to claim 1 , wherein R 1 is (L)-ornityl-(D)-ornitylamino, and R 2 and R 3 are hydrogen.
6. The compound according to claim 1 , wherein R 1 is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N,-bis(2-aminoethyl)amino]valeryl]amino, and R 2 and R 3 are hydrogen.
7. The compound according to claim 1 , wherein R 1 is N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R 2 and R 3 are hydrogen.
8. The compound according to claim 1 , wherein R 1 is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, and R 2 and R 3 are hydrogen.
9. The compound according to any of claims 1 to 3 , wherein R 1 is N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)aminol]valeryl]amino, and R 2 and R 3 are hydrogen.
10. The compound according to claim 1 wherein R 2 is methyl and R 3 is hydrogen.
11. The compound according to claim 1 wherein R 2 is hydrogen and R 3 is hydroxyl.
12. A pharmaceutical composition comprising a mixture of a pharmaceutically acceptable carrier and an effective amount of a compound of the formula:
wherein
R 1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;
R 2 is hydrogen or methyl;
R 3 is hydrogen or hydroxy;
or a pharmaceutically acceptable salt thereof.
13. A method for the prophylactic and/or therapeutic treatment of mycoses which comprises administering to a human being or an animal an effective amount of the compound of the formula:
wherein
R 1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;
R 2 is hydrogen or methyl;
R 3 is hydrogen or hydroxy;
or a pharmaceutically acceptable salt thereof, thereby producing antifungal activity.